Diligence memo · auto-generated · as of July 2, 2026
Levo Therapeutics, Inc.
Levo Therapeutics, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Levo Therapeutics, Inc. operates in Pharma, based in SKOKIE.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Levo Therapeutics, Inc. has raised $87M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $47M on 2017-08-04.
Most recent recorded round closed around 2019-09-04.
Valuation (modeled)modeled
Provath models Levo Therapeutics, Inc. at approximately $1.4B (range $130M–$3.7B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.70× the median modeled value of Series C Pharma companies in 2019–2021 (7 peers) — value vs value, same stage and era. Within the normal band (70% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 25 months.
Last raise 6.8 yr ago; this sector typically re-raises about every 16 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.2× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 89% of Pharma peers (310 compared).
Modeled value ranks above 92% of those peers.
Closest niche peers: Ansun Biopharma, Inc., Integrated Oncology Network Holdco, LLC, Tallac Therapeutics, Inc., Elevation Oncology, Inc., CERo Therapeutics, Inc..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.